Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C

Chronic hepatitis C is a common cause of liver-related morbidity and mortality. Ledipasvir/sofosbuvir is a combination of 2 direct-acting antiviral agents that has been approved for use in patients with genotype 1, 4, 5, or 6. This approval is based on multiple phase 3 studies in which the rate of s...

Full description

Saved in:
Bibliographic Details
Published in:Clinical Medicine Insights: Therapeutics 2017-06, Vol.2017 (9), p.1-6-012
Main Authors: Childs-Kean, Lindsey M, Jourjy, Jacqueline
Format: Article
Language:English
Subjects:
Antiviral drugs
Authorship
Dosage and administration
Drug dosages
Drug therapy
Genotype & phenotype
Hepatitis
Hepatitis C
Hepatitis C virus
HIV
Human immunodeficiency virus
Infectious diseases
Liver diseases
Patients
Peer review
Sofosbuvir
Studies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic hepatitis C is a common cause of liver-related morbidity and mortality. Ledipasvir/sofosbuvir is a combination of 2 direct-acting antiviral agents that has been approved for use in patients with genotype 1, 4, 5, or 6. This approval is based on multiple phase 3 studies in which the rate of sustained virologic response exceeded 90% for 12 or 24 weeks of treatment, depending on the patient population. For some patients, the addition of ribavirin is required. Ledipasvir/sofosbuvir is well tolerated, with the most commonly reported adverse events being fatigue and headaches.
ISSN:1179-559X
1179-559X
DOI:10.1177/1179559X17719125